MR001

DRUG2 trials

Sponsors

Nanfang Hospital, Southern Medical University, Shenzhen Majory Biotechnology Co., Ltd.

Conditions

Advanced Solid TumorsPancreatic Ductal Adenocarcinoma (PDAC)

Phase 1

First-In-Human Study of Bispecific Antibody MR001 In Subjects With Advanced Solid Tumors

Not yet recruitingNCT06134531

Nanfang Hospital, Southern Medical UniversityAdvanced Solid Tumors

Start: 2023-11-30End: 2026-10-31Target: 31Updated: 2023-11-18

A Study of MR001 Combined With Chemotherapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) After First-line Therapy

RecruitingNCT07235202

Shenzhen Majory Biotechnology Co., Ltd.Pancreatic Ductal Adenocarcinoma (PDAC)

Start: 2025-12-24End: 2028-12-22Target: 45Updated: 2025-12-31